Product Data Sheet

APC/Fire™ 750 anti-human B7-H4

Catalog # / 2390590 / 100 tests

Size: 2390585 / 25 tests

Clone: MIH43

Isotype: Mouse IgG1, κ

Immunogen: BCMA-mouse IgG Fc fusion protein

Reactivity: Human

Preparation: The antibody was purified by affinity

chromatography and conjugated with

APC/Fire™ 750 under optimal


conditions.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human B7-H4 transfected P815 cells were stained with human B7-H4 (clone MIH43) APC/Fire™ 750 (filled histogram) or mouse IgG1, κ APC/Fire™ 750 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells in 100 μ l staining

volume or 5 μ l per 100 μ l of whole blood.

* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum

emission of 787 nm.

Application

Notes:

Additional reported applications (for the relevant formats) includes

immunofluorescence².

Application References:

1. Quandt D, et al. 2011. Clin. Cancer Res. 17:3100.

2. Smith JB, et al. 2014. Gynecol. Oncol. 134:181. (FC, IF)

Description: B7-H4, also known as VTCN1, is a type I transmembrane protein and member

of the B7 family. Its extracellular region consists of one IgV-like and one IgC-like domain. B7-H4 expression has been reported on activated T cells, B

cells, monocytes, and dendritic cells. On T cells, B7-H4 inhibits

proliferation, cytokine secretion, and cytotoxicity. B7-H4 is also expressed

by different carcinomas including renal, gastric, breast, ovarian and melanoma. Its expression is associated with a poor prognosis.

Antigen 1. Fauci JM, et al. 201 References: 2. Chen C. et al. 2012.

1. Fauci JM, et al. 2012. Gynecol. Oncol. 127:420.

2. Chen C, et al. 2012. J. Immunother. 35:354.

3. Guo G, et al. 2012. Clin. Rheumatol. 31:271.

4. Arigami T, et al. 2010. J. Surg. Oncol. 102:748.